Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Hosted on MSN2h
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Vertex Energy files restructuring plan after filing for bankruptcy
In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...
Hosted on MSN17h
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...
The Boston Globe13d
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, ...
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug
Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Beyond The Numbers: 12 Analysts Discuss Vertex Stock
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...
Vertex Poised for Growth: Strategic Acquisitions and Market Positioning Drive Buy Rating
Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...
Vertex's painkiller results match placebo in study, shares tumble
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...
Business Insider2d
Vertex initiated with a Buy at DA Davidson
DA Davidson analyst William Jellison initiated coverage of Vertex (VERX) with a Buy rating and $62 price target Vertex “exhibits several characteristics exemplifying sustained value-capture and ...